| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
75,280,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Xenon Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing therapeutics for patients with neurological disorders. Co.'s product pipeline of neurology-focused therapies focus on epilepsy. Co.'s product candidates include: XEN1101, a Kv7 potassium channel opener for the treatment of epilepsy and potentially other neurological disorders, such as major depressive disorder; and XEN496, a Kv7 potassium channel opener for the treatment of KCNQ2 developmental and epileptic encephalopathy. In addition, Co. has a license and collaboration agreement with Neurocrine Biosciences Inc. to develop NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of epilepsy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
22,229 |
48,805 |
236,705 |
576,095 |
| Total Sell Value |
$1,027,488 |
$2,098,369 |
$9,481,770 |
$22,449,223 |
| Total People Sold |
3 |
4 |
7 |
10 |
| Total Sell Transactions |
3 |
6 |
11 |
22 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pimstone Simon N. |
|
– • – |
2023-06-01 |
4 |
S |
$38.78 |
$1,231,247 |
D/D |
(31,713) |
6,000 |
|
- |
|
| Pimstone Simon N. |
|
– • – |
2023-06-01 |
4 |
D |
$38.53 |
$870,971 |
D/D |
(22,605) |
30,255 |
|
- |
|
| Pimstone Simon N. |
|
– • – |
2023-06-01 |
4 |
OE |
$7.69 |
$870,855 |
D/D |
54,318 |
51,000 |
|
- |
|
| Pimstone Simon N. |
|
– • – |
2023-05-31 |
4 |
S |
$38.53 |
$2,420,051 |
D/D |
(62,526) |
6,000 |
|
- |
|
| Pimstone Simon N. |
|
– • – |
2023-05-31 |
4 |
D |
$38.37 |
$1,124,586 |
D/D |
(29,309) |
32,856 |
|
- |
|
| Pimstone Simon N. |
|
– • – |
2023-05-31 |
4 |
OE |
$9.85 |
$1,181,875 |
D/D |
79,835 |
56,000 |
|
- |
|
| Pimstone Simon N. |
|
– • – |
2023-05-30 |
4 |
S |
$38.63 |
$1,453,672 |
D/D |
(37,006) |
18,000 |
|
- |
|
| Mortimer Ian |
PRESIDENT & CEO |
• • – |
2023-05-24 |
4 |
S |
$41.37 |
$1,310,931 |
D/D |
(31,655) |
31,302 |
|
- |
|
| Mortimer Ian |
PRESIDENT & CEO |
• • – |
2023-05-24 |
4 |
D |
$41.84 |
$518,105 |
D/D |
(12,383) |
32,709 |
|
- |
|
| Mortimer Ian |
PRESIDENT & CEO |
• • – |
2023-05-24 |
4 |
OE |
$9.44 |
$665,536 |
D/D |
69,340 |
33,880 |
|
- |
|
| Kenney Christopher John |
Chief Medical Officer |
• – – |
2023-03-24 |
4 |
S |
$35.01 |
$24,507 |
D/D |
(700) |
0 |
|
- |
|
| Pimstone Simon N. |
Director |
– • – |
2023-03-07 |
4 |
S |
$36.94 |
$711,199 |
D/D |
(19,232) |
55,006 |
|
- |
|
| Pimstone Simon N. |
Director |
– • – |
2023-03-07 |
4 |
D |
$37.13 |
$140,277 |
D/D |
(3,778) |
63,248 |
|
- |
|
| Pimstone Simon N. |
Director |
– • – |
2023-03-07 |
4 |
OE |
$2.59 |
$190,225 |
D/D |
72,016 |
64,866 |
|
- |
|
| Azab Mohammad |
Director |
– • – |
2022-12-12 |
4 |
OE |
$2.68 |
$8,270 |
D/D |
3,086 |
69,905 |
|
- |
|
| Patou Gary |
Director |
– • – |
2022-11-25 |
4 |
S |
$34.79 |
$67,390 |
D/D |
(1,937) |
23,573 |
|
- |
|
| Patou Gary |
Director |
– • – |
2022-11-25 |
4 |
D |
$34.37 |
$4,124 |
D/D |
(120) |
25,510 |
|
- |
|
| Patou Gary |
Director |
– • – |
2022-11-25 |
4 |
OE |
$2.68 |
$5,513 |
D/D |
2,057 |
25,630 |
|
- |
|
| Patou Gary |
Director |
– • – |
2022-11-23 |
4 |
S |
$34.33 |
$70,610 |
D/D |
(2,057) |
23,573 |
|
- |
|
| Aulin Sherry |
Chief Financial Officer |
• – – |
2022-09-02 |
4 |
S |
$39.57 |
$607,597 |
D/D |
(15,355) |
0 |
|
- |
|
| Aulin Sherry |
Chief Financial Officer |
• – – |
2022-09-02 |
4 |
D |
$39.53 |
$130,172 |
D/D |
(3,293) |
15,355 |
|
- |
|
| Aulin Sherry |
Chief Financial Officer |
• – – |
2022-09-02 |
4 |
OE |
$3.10 |
$130,061 |
D/D |
18,648 |
18,648 |
|
- |
|
| Robin Sherrington |
EVP, Strategy & Innovation |
• – – |
2022-09-01 |
4 |
S |
$38.03 |
$1,675,476 |
D/D |
(43,879) |
16,796 |
|
- |
|
| Robin Sherrington |
EVP, Strategy & Innovation |
• – – |
2022-09-01 |
4 |
D |
$38.81 |
$237,556 |
D/D |
(6,121) |
60,675 |
|
- |
|
| Robin Sherrington |
EVP, Strategy & Innovation |
• – – |
2022-09-01 |
4 |
OE |
$4.75 |
$237,500 |
D/D |
50,000 |
66,796 |
|
- |
|
55 Records found
|
|
Page 1 of 3 |
|
|
